REPORT ID 3080

EMEA (Europe, Middle East and Africa) Irritable Bowel Syndrome Treatment Market Report 2017

Publish Date
12-Dec-17
Pages
103
Format
Electronic (PDF)

In this report, the EMEA Irritable Bowel Syndrome Treatment market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Pcs), revenue (Million USD), market share and growth rate of Irritable Bowel Syndrome Treatment for these regions, from 2012 to 2022 (forecast)
    Europe: Germany, France, UK, Russia, Italy and Benelux;
    Middle East: Saudi Arabia, Israel, UAE and Iran;
    Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Irritable Bowel Syndrome Treatment market competition by top manufacturers/players, with Irritable Bowel Syndrome Treatment sales volume (K Pcs), price (USD/Pcs), revenue (Million USD) and market share for each manufacturer/player; the top players including
    Abbott Laboratories
    Synergy Pharmaceuticals, Inc.
    Sucampo Pharmaceuticals, Inc.
    Valeant Pharmaceuticals International, Inc.
    Ardelyx, Inc.
    Astellas Pharma Inc.
    Novartis AG
    GlaxoSmithKline plc.
    Ironwood Pharmaceuticals, Inc.

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into
    Lubiprostone
    Linaclotide
    Eluxadoline
    Rifaximin
    Ramosetron Hydrochloride
    Others

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Hospital
    Clinic
    Home Care

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

EMEA (Europe, Middle East and Africa) Irritable Bowel Syndrome Treatment Market Report 2017
1 Irritable Bowel Syndrome Treatment Overview
    1.1 Product Overview and Scope of Irritable Bowel Syndrome Treatment
    1.2 Classification of Irritable Bowel Syndrome Treatment
        1.2.1 EMEA Irritable Bowel Syndrome Treatment Market Size (Sales) Comparison by Type (2012-2022)
        1.2.2 EMEA Irritable Bowel Syndrome Treatment Market Size (Sales) Market Share by Type (Product Category) in 2016
        1.2.3 Lubiprostone
        1.2.4 Linaclotide
        1.2.5 Eluxadoline
        1.2.6 Rifaximin
        1.2.7 Ramosetron Hydrochloride
        1.2.8 Others
    1.3 EMEA Irritable Bowel Syndrome Treatment Market by Application/End Users
        1.3.1 EMEA Irritable Bowel Syndrome Treatment Sales (Volume) and Market Share Comparison by Application (2012-2022
        1.3.2 Hospital
        1.3.3 Clinic
        1.3.4 Home Care
    1.4 EMEA Irritable Bowel Syndrome Treatment Market by Region
        1.4.1 EMEA Irritable Bowel Syndrome Treatment Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 Europe Status and Prospect (2012-2022)
        1.4.3 Middle East Status and Prospect (2012-2022)
        1.4.4 Africa Status and Prospect (2012-2022)
    1.5 EMEA Market Size (Value and Volume) of Irritable Bowel Syndrome Treatment (2012-2022)
        1.5.1 EMEA Irritable Bowel Syndrome Treatment Sales and Growth Rate (2012-2022)
        1.5.2 EMEA Irritable Bowel Syndrome Treatment Revenue and Growth Rate (2012-2022)

2 EMEA Irritable Bowel Syndrome Treatment Competition by Manufacturers/Players/Suppliers, Region, Type and Application
    2.1 EMEA Irritable Bowel Syndrome Treatment Market Competition by Players/Manufacturers
        2.1.1 EMEA Irritable Bowel Syndrome Treatment Sales Volume and Market Share of Major Players (2012-2017)
        2.1.2 EMEA Irritable Bowel Syndrome Treatment Revenue and Share by Players (2012-2017)
        2.1.3 EMEA Irritable Bowel Syndrome Treatment Sale Price by Players (2012-2017)
    2.2 EMEA Irritable Bowel Syndrome Treatment (Volume and Value) by Type/Product Category
        2.2.1 EMEA Irritable Bowel Syndrome Treatment Sales and Market Share by Type (2012-2017)
        2.2.2 EMEA Irritable Bowel Syndrome Treatment Revenue and Market Share by Type (2012-2017)
        2.2.3 EMEA Irritable Bowel Syndrome Treatment Sale Price by Type (2012-2017)
    2.3 EMEA Irritable Bowel Syndrome Treatment (Volume) by Application
    2.4 EMEA Irritable Bowel Syndrome Treatment (Volume and Value) by Region
        2.4.1 EMEA Irritable Bowel Syndrome Treatment Sales and Market Share by Region (2012-2017)
        2.4.2 EMEA Irritable Bowel Syndrome Treatment Revenue and Market Share by Region (2012-2017)
        2.4.3 EMEA Irritable Bowel Syndrome Treatment Sales Price by Region (2012-2017)

3 Europe Irritable Bowel Syndrome Treatment (Volume, Value and Sales Price), by Players, Countries, Type and Application
    3.1 Europe Irritable Bowel Syndrome Treatment Sales and Value (2012-2017)
        3.1.1 Europe Irritable Bowel Syndrome Treatment Sales Volume and Growth Rate (2012-2017)
        3.1.2 Europe Irritable Bowel Syndrome Treatment Revenue and Growth Rate (2012-2017)
    3.2 Europe Irritable Bowel Syndrome Treatment Sales and Market Share by Type
    3.3 Europe Irritable Bowel Syndrome Treatment Sales and Market Share by Application
    3.4 Europe Irritable Bowel Syndrome Treatment Sales Volume and Value (Revenue) by Countries
        3.4.1 Europe Irritable Bowel Syndrome Treatment Sales Volume by Countries (2012-2017)
        3.4.2 Europe Irritable Bowel Syndrome Treatment Revenue by Countries (2012-2017)
        3.4.3 Germany Irritable Bowel Syndrome Treatment Sales and Growth Rate (2012-2017)
        3.4.4 France Irritable Bowel Syndrome Treatment Sales and Growth Rate (2012-2017)
        3.4.5 UK Irritable Bowel Syndrome Treatment Sales and Growth Rate (2012-2017)
        3.4.6 Russia Irritable Bowel Syndrome Treatment Sales and Growth Rate (2012-2017)
        3.4.7 Italy Irritable Bowel Syndrome Treatment Sales and Growth Rate (2012-2017)
        3.4.8 Benelux Irritable Bowel Syndrome Treatment Sales and Growth Rate (2012-2017)

4 Middle East Irritable Bowel Syndrome Treatment (Volume, Value and Sales Price), by Region, Type and Application
    4.1 Middle East Irritable Bowel Syndrome Treatment Sales and Value (2012-2017)
        4.1.1 Middle East Irritable Bowel Syndrome Treatment Sales Volume and Growth Rate (2012-2017)
        4.1.2 Middle East Irritable Bowel Syndrome Treatment Revenue and Growth Rate (2012-2017)
    4.2 Middle East Irritable Bowel Syndrome Treatment Sales and Market Share by Type
    4.3 Middle East Irritable Bowel Syndrome Treatment Sales and Market Share by Application
    4.4 Middle East Irritable Bowel Syndrome Treatment Sales Volume and Value (Revenue) by Countries
        4.4.1 Middle East Irritable Bowel Syndrome Treatment Sales Volume by Countries (2012-2017)
        4.4.2 Middle East Irritable Bowel Syndrome Treatment Revenue by Countries (2012-2017)
        4.4.3 Saudi Arabia Irritable Bowel Syndrome Treatment Sales and Growth Rate (2012-2017)
        4.4.4 Israel Irritable Bowel Syndrome Treatment Sales and Growth Rate (2012-2017)
        4.4.5 UAE Irritable Bowel Syndrome Treatment Sales and Growth Rate (2012-2017)
        4.4.6 Iran Irritable Bowel Syndrome Treatment Sales and Growth Rate (2012-2017)

5 Africa Irritable Bowel Syndrome Treatment (Volume, Value and Sales Price) by Players, Countries, Type and Application
    5.1 Africa Irritable Bowel Syndrome Treatment Sales and Value (2012-2017)
        5.1.1 Africa Irritable Bowel Syndrome Treatment Sales Volume and Growth Rate (2012-2017)
        5.1.2 Africa Irritable Bowel Syndrome Treatment Revenue and Growth Rate (2012-2017)
    5.2 Africa Irritable Bowel Syndrome Treatment Sales and Market Share by Type
    5.3 Africa Irritable Bowel Syndrome Treatment Sales and Market Share by Application
    5.4 Africa Irritable Bowel Syndrome Treatment Sales Volume and Value (Revenue) by Countries
        5.4.1 Africa Irritable Bowel Syndrome Treatment Sales Volume by Countries (2012-2017)
        5.4.2 Africa Irritable Bowel Syndrome Treatment Revenue by Countries (2012-2017)
        5.4.3 South Africa Irritable Bowel Syndrome Treatment Sales and Growth Rate (2012-2017)
        5.4.4 Nigeria Irritable Bowel Syndrome Treatment Sales and Growth Rate (2012-2017)
        5.4.5 Egypt Irritable Bowel Syndrome Treatment Sales and Growth Rate (2012-2017)
        5.4.6 Algeria Irritable Bowel Syndrome Treatment Sales and Growth Rate (2012-2017)

6 EMEA Irritable Bowel Syndrome Treatment Manufacturers/Players Profiles and Sales Data
    6.1 Abbott Laboratories
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Irritable Bowel Syndrome Treatment Product Type, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 Abbott Laboratories Irritable Bowel Syndrome Treatment Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 Synergy Pharmaceuticals, Inc.
        6.2.1 Company Basic Information, Manufacturing Base and Competitors
        6.2.2 Irritable Bowel Syndrome Treatment Product Type, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Synergy Pharmaceuticals, Inc. Irritable Bowel Syndrome Treatment Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 Sucampo Pharmaceuticals, Inc.
        6.3.1 Company Basic Information, Manufacturing Base and Competitors
        6.3.2 Irritable Bowel Syndrome Treatment Product Type, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Sucampo Pharmaceuticals, Inc. Irritable Bowel Syndrome Treatment Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 Valeant Pharmaceuticals International, Inc.
        6.4.1 Company Basic Information, Manufacturing Base and Competitors
        6.4.2 Irritable Bowel Syndrome Treatment Product Type, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 Valeant Pharmaceuticals International, Inc. Irritable Bowel Syndrome Treatment Sales, Revenue, Price and Gross Margin (2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 Ardelyx, Inc.
        6.5.1 Company Basic Information, Manufacturing Base and Competitors
        6.5.2 Irritable Bowel Syndrome Treatment Product Type, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Ardelyx, Inc. Irritable Bowel Syndrome Treatment Sales, Revenue, Price and Gross Margin (2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 Astellas Pharma Inc.
        6.6.1 Company Basic Information, Manufacturing Base and Competitors
        6.6.2 Irritable Bowel Syndrome Treatment Product Type, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 Astellas Pharma Inc. Irritable Bowel Syndrome Treatment Sales, Revenue, Price and Gross Margin (2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 Novartis AG
        6.7.1 Company Basic Information, Manufacturing Base and Competitors
        6.7.2 Irritable Bowel Syndrome Treatment Product Type, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 Novartis AG Irritable Bowel Syndrome Treatment Sales, Revenue, Price and Gross Margin (2012-2017)
        6.7.4 Main Business/Business Overview
    6.8 GlaxoSmithKline plc.
        6.8.1 Company Basic Information, Manufacturing Base and Competitors
        6.8.2 Irritable Bowel Syndrome Treatment Product Type, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 GlaxoSmithKline plc. Irritable Bowel Syndrome Treatment Sales, Revenue, Price and Gross Margin (2012-2017)
        6.8.4 Main Business/Business Overview
    6.9 Ironwood Pharmaceuticals, Inc.
        6.9.1 Company Basic Information, Manufacturing Base and Competitors
        6.9.2 Irritable Bowel Syndrome Treatment Product Type, Application and Specification
            6.9.2.1 Product A
            6.9.2.2 Product B
        6.9.3 Ironwood Pharmaceuticals, Inc. Irritable Bowel Syndrome Treatment Sales, Revenue, Price and Gross Margin (2012-2017)
        6.9.4 Main Business/Business Overview

7 Irritable Bowel Syndrome Treatment Manufacturing Cost Analysis
    7.1 Irritable Bowel Syndrome Treatment Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Irritable Bowel Syndrome Treatment

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Irritable Bowel Syndrome Treatment Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Irritable Bowel Syndrome Treatment Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 EMEA Irritable Bowel Syndrome Treatment Market Forecast (2017-2022)
    11.1 EMEA Irritable Bowel Syndrome Treatment Sales, Revenue and Price Forecast (2017-2022)
        11.1.1 EMEA Irritable Bowel Syndrome Treatment Sales and Growth Rate Forecast (2017-2022)
        11.1.2 EMEA Irritable Bowel Syndrome Treatment Revenue and Growth Rate Forecast (2017-2022)
        11.1.3 EMEA Irritable Bowel Syndrome Treatment Price and Trend Forecast (2017-2022)
    11.2 EMEA Irritable Bowel Syndrome Treatment Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.3 Europe Irritable Bowel Syndrome Treatment Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.4 Middle Eastt Irritable Bowel Syndrome Treatment Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.5 Africa Irritable Bowel Syndrome Treatment Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.6 EMEA Irritable Bowel Syndrome Treatment Sales Forecast by Type (2017-2022)
    11.7 EMEA Irritable Bowel Syndrome Treatment Sales Forecast by Application (2017-2022)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer